IP Library Granted Patent US 10,456,362
Granted Patent B2
US 10,456,362 · App. 15/561,118 · Granted Oct 29, 2019

Stabilized pharmaceutical composition and method for preparing same

Inventors: Joong-Woong Cho (Daejeon, KR); Gyeong-Hae Kim (Daejeon, KR); Min-Hyo Seo (Daejeon, KR); Sa-Won Lee (Daejeon, KR)
Assignee: SAMYANG BIOPHARMACEUTICALS CORPORATION
A61K9/19A61K9/0019A61K9/08A61K31/519A61K47/02A61K47/18A61K47/20A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,456,362
App. No.
15/561,118
Granted
Oct 29, 2019
Kind
B2
Abstract

Provided are a composition containing an unstable drug against oxidation like pemetrexed with improved stability and a preparation method thereof, by removing oxygen during the preparation. The method is readily applicable for manufacturing by freezing and degassing in a sealed chamber, and can provide formulations with significantly increased stability for the unstable drug against oxidation.

Claims (18)

1. A method of preparing a pharmaceutical composition, comprising:

(a) preparing a solution comprising pemetrexed or a pharmaceutically acceptable salt thereof, and an aqueous solvent in a container;

(b) freezing the solution in the container to produce a frozen product; and

(c) degassing the frozen product under reduced pressure to obtain a degassed and frozen product,

wherein the degassed and frozen product comprises 95 to 100 parts by weight of the solvent per 100 parts by weight of the solvent contained in the solution of step (a), and

the steps of (b) and (c) are performed in a sealed chamber.

2. The method of claim 1 , wherein the degassing in step (c) is performed to attain a dissolved oxygen concentration of 1.5 ppm or lower.

3. The method of claim 1 , wherein the degassing in step (c) is performed for 12 hours or shorter.

4. The method of claim 1 , wherein the solution of step (a) has not been degassed.

5. The method of claim 1 , wherein the solution further comprises at least one selected from the group consisting of pharmaceutically acceptable excipients and pH adjusting agents.

6. The method of claim 5 , wherein the excipient is mannitol, or the pH adjusting agent is hydrochloric acid, sodium hydroxide, or a mixture thereof.

7. The method of claim 1 , wherein the solution further comprises an antioxidant.

8. The method of claim 7 , wherein the antioxidant is monothioglycerol, sodium sulfite, acetylcysteine or a mixture thereof.

9. The method of claim 1 , wherein the freezing in step (b) is performed at −20° C. or lower.

10. The method of claim 1 , wherein the reduced pressure of step (c) is 2,000 mTorr or lower.

11. The method of claim 1 , wherein the method further comprises a step of sealing the container or a step of filling the container with nitrogen followed by sealing, after step (c).

12. The method of claim 1 , wherein the method further comprises thawing the degassed and frozen product, after step (c).

13. The method of claim 11 , wherein the method further comprises thawing the degassed and frozen product, after the sealing the container.

Assignments (2)
MERGER Recorded Nov 3, 2021
From: SAMYANG BIOPHARMACEUTICALS CORPORATION
To: SAMYANG HOLDINGS CORPORATION
Reel/Frame 058013/0766 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2017
From: CHO, JOONG-WOONG; KIM, GYEONG-HAE; SEO, MIN-HYO; LEE, SA-WON
To: SAMYANG BIOPHARMACEUTICALS CORPORATION
Reel/Frame 043678/0409 →
Priority Claims (1)
KR 10-2015-0074540 · May 28, 2015 · national
Continuity (1)
Related Publication 20180125786A1 · May 10, 2018